Literature DB >> 27659803

Complete resection for pleomorphic lung cancer with a high serum IL-6 level: a case report.

Soichi Oka1, Hiroki Matsumiya2, Shuichi Shinohara2, Taiji Kuwata2, Masaru Takenaka2, Yasuhiro Chikaishi2, Ayako Hirai2, Naoko Imanishi2, Koji Kuroda2, Hidetaka Uramoto2, Fumihiro Tanaka2.   

Abstract

BACKGROUND: Pleomorphic lung cancer cells have been reported to produce cytokines, resulting in systemic reactions. Recently, the autonomous production of hematopoietic cytokines (granulocyte colony-stimulating factor [G-CSF], granulocyte-macrophage colony-stimulating factor [GM-CSF], and interleukin-6 [IL-6]) was observed in some of these patients. CASE
PRESENTATION: We herein report a case of complete resection of right pleomorphic lung cancer producing IL-6. The patient had a high-grade fever before surgery, and a blood examination showed high IL-6 and CRP levels in the serum. After surgery, the patient no longer had a fever, and the elevated serum IL-6 levels had dropped to values less than those before the operation. Immunohistochemically, the carcinoma cells were faintly or focally positive for IL-6 and negative for G-CSF.
CONCLUSIONS: The symptoms in the present case were dramatically improved by surgery. In addition, an immunohistochemical examination showed that the cancer cells were positive for IL-6.

Entities:  

Year:  2016        PMID: 27659803      PMCID: PMC5033800          DOI: 10.1186/s40792-016-0232-8

Source DB:  PubMed          Journal:  Surg Case Rep        ISSN: 2198-7793


Background

Lung cancer cells have been reported to produce several cytokines and growth factors, especially interleukin (IL)-6 and granulocyte colony-stimulating factor (G-CSF), resulting in various systemic reactions [1-4]. We experienced a case of pleomorphic lung cancer producing IL-6.

Case presentation

A 39-year-old Japanese male presented at our hospital due to an abnormal chest computed tomography (CT) scan showing a 35 × 25 × 25 mm tumor located in the right hilar region. This tumor was suspected to have invaded the right main bronchus and right main pulmonary artery (Fig. 1). 18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography showed moderate FDG uptake within the tumor (Fig. 1). There was no significant distant metastasis. The patient had general fatigue and appetite loss and had a fever for about 3 weeks. He had no remarkable medical history. His tumor marker levels were not elevated. The findings from laboratory tests, including a panel of antibodies for autoimmune processes, and an immunohistochemical analysis for lymphoma were all negative. His serum IL-6 levels were markedly high (28.2 pg/ml [<2.41]), but his serum G-CSF levels were not.
Fig. 1

Preoperative imaging studies. Computed tomography of the chest showing the localization of the tumor. The tumor is located in the right hilar. The tumor surrounds the right upper bronchus (a). 18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography shows moderate FDG uptake within the tumor (b). The pink-colored area indicates that the maximum standardized uptake value is 8.1 or more

Preoperative imaging studies. Computed tomography of the chest showing the localization of the tumor. The tumor is located in the right hilar. The tumor surrounds the right upper bronchus (a). 18-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography shows moderate FDG uptake within the tumor (b). The pink-colored area indicates that the maximum standardized uptake value is 8.1 or more We performed endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). The tumor was found to be a carcinoma (suspected giant cell carcinoma; clinical-T2aN1M0 stage IIA), so we performed right upper sleeve lobectomy, because of the tumor invading the base of the right upper lobe bronchus. The surgery was successful, with no major postoperative complications. The patient was discharged in a healthy condition 10 days after the surgery. He no longer had a fever, and his post-surgery 9-day serum IL-6 level was 10.9 pg/ml, which was lower than that before the operation. Pathologically, the tumor showed proliferation of atypical epithelial cells having pleomorphic nuclei and prominent nucleoli arranged in a lepidic, acinar, or solid growth fashion (adenocarcinoma component), mixed with bi- and multinucleated cells with occasional emperipolesis (giant cell carcinoma component) and stroma, findings which were consistent with a pleomorphic carcinoma. Immunohistochemically, the carcinoma cells were faintly or focally (50 % tumor cells positive) positive for IL-6 but negative for G-CSF (Fig. 2). Giant cell proportions were 30 % in this tumor. IL-6 positive carcinoma cells were 50 % in these tumor cells which include the adenocarcinoma component. There were no lung abscesses and inflammatory changes. Finally, this case’s pathological stage was T2aN1M0 stage IIA pleomorphic carcinoma. We performed adjuvant chemotherapy (three cycles of cisplatin and pemetrexed) after surgery. This patient is alive and recurrence-free 1 year after surgery.
Fig. 2

The figure shows the pathological findings. The tumor shows a proliferation of atypical epithelial cells having pleomorphic nuclei and prominent nucleoli arranged in a lepidic, acinar, or solid growth fashion (adenocarcinoma component), admixed with bi-nucleated or multinucleated cells with occasional emperipolesis (giant cell carcinoma component) with stromal, consistent with pleomorphic carcinoma (a). Immunohistochemically, the carcinoma cells are faintly or focally positive for IL-6 (b)

The figure shows the pathological findings. The tumor shows a proliferation of atypical epithelial cells having pleomorphic nuclei and prominent nucleoli arranged in a lepidic, acinar, or solid growth fashion (adenocarcinoma component), admixed with bi-nucleated or multinucleated cells with occasional emperipolesis (giant cell carcinoma component) with stromal, consistent with pleomorphic carcinoma (a). Immunohistochemically, the carcinoma cells are faintly or focally positive for IL-6 (b)

Conclusions

This report has two important implications. First, the symptoms in this case were dramatically improved by surgery. The patient initially presented with a high-grade fever and elevated C-reactive protein (CRP) levels and serum concentrations of IL-6. Following right upper sleeve lobectomy, however, his serum IL-6 level was 10.9 pg/ml, which was lower than pre-operation. CRP-elevated concentrations normalized, and the fever dissipated after surgery. Second, the findings from an immunohistochemical examination showed that the cancer cells were positive for IL-6. The elevated IL-6 levels in this patient may have contributed to his high-grade fever and high CRP levels. This case was pleomorphic carcinoma. These cytokines have been reportedly produced by lung cancer, especially by large cell carcinomas. There were a few cases reported that pleomorphic lung cancer produced IL-6 [3]. Thus, our report is valuable. Kasuga et al. reported that tumor-related leukocytosis is an ominous prognostic sign in patients with lung cancer [5]. Further, Mochizuki et al. reported that pleomorphic carcinoma should be considered as an aggressive disease and massive necrosis should be routinely reported and used as a factor in clinical assessments [6]. In our case, this patient has experienced no recurrence and no leukocytosis for 1 year after his surgery. And, pathologically, this tumor has a few necrosis areas. However, subsequent careful follow-up should be continued. Finally, several reports described patients of the pleomorphic lung cancer to have a fever and cancer cell producing IL-6 cytokine [3, 5]. Therefore, measurement of IL-6 may be help to diagnose the tumor before therapy and predict the recurrence.
  5 in total

1.  Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma.

Authors:  I Kasuga; S Makino; H Kiyokawa; H Katoh; Y Ebihara; K Ohyashiki
Journal:  Cancer       Date:  2001-11-01       Impact factor: 6.860

2.  Establishment of a large cell lung cancer cell line (Y-ML-1B) producing granulocyte colony-stimulating factor.

Authors:  Yoshitaka Sekido; Mitsuo Sato; Noriyasu Usami; Kikuo Shigemitsu; Shoichi Mori; Osamu Maeda; Toyoharu Yokoi; Yoshinori Hasegawa; Hiromu Yoshioka; Kaoru Shimokata
Journal:  Cancer Genet Cytogenet       Date:  2002-08

3.  Pleomorphic carcinoma of the lung: clinicopathologic characteristics of 70 cases.

Authors:  Takahiro Mochizuki; Genichiro Ishii; Kanji Nagai; Junji Yoshida; Mitsuyo Nishimura; Tetsuya Mizuno; Tomoyuki Yokose; Kazuya Suzuki; Atsushi Ochiai
Journal:  Am J Surg Pathol       Date:  2008-11       Impact factor: 6.394

4.  Serum levels of cytokines in patients with untreated primary lung cancer.

Authors:  N Katsumata; K Eguchi; M Fukuda; N Yamamoto; Y Ohe; F Oshita; T Tamura; T Shinkai; N Saijo
Journal:  Clin Cancer Res       Date:  1996-03       Impact factor: 12.531

5.  A pleomorphic carcinoma of the lung producing multiple cytokines and forming a rapidly progressive mass-like opacity.

Authors:  Masataka Matsumoto; Takashi Nakayama; Daiki Inoue; Kazufumi Takamatsu; Ryo Itotani; Manabu Ishitoko; Shinko Suzuki; Minoru Sakuramoto; Yoshiaki Yuba; Osamu Yoshie; Masaya Takemura; Motonari Fukui
Journal:  BMC Cancer       Date:  2014-08-13       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.